A new study found that using infusions of an experimental liquid radiation reduces the risk of death by 38 percent and disease progression by 60 percent for patients with advanced prostate cancer. MSK’s Michael Morris is interviewed. 

Read more here

“Copanlisib is the first PI3 kinase inhibitor to be safely combined with rituximab in a randomized phase 3 setting, and the first to demonstrate broad and superior efficacy in combination with rituximab [for] patients with relapsed follicular lymphoma or marginal zone lymphoma, ” Matthew J. Matasar, MD, medical oncologist and lymphoma specialist at Memorial Sloan Kettering Cancer Center, said during a presentation. “[This represents] a potential new treatment option [for] this population.” 

Read more here

The Memorial Sloan Kettering Cancer Center held its annual Pediatric Convocation virtually Thursday due to the pandemic.

Trumbull senior Sona Kocinsky and her classmates aren't from the same school or even the same state. They have something else in common - strength and resilience.

The teens are all current or former pediatric cancer patients now celebrating a major milestone - one that wasn't a given they'd see.

Read more here